Literature DB >> 31844909

GCN2 is essential for CD8+ T cell survival and function in murine models of malignant glioma.

Aida Rashidi1, Jason Miska1, Catalina Lee-Chang1, Deepak Kanojia1, Wojciech K Panek1, Aurora Lopez-Rosas1, Peng Zhang1, Yu Han1, Ting Xiao1, Katarzyna C Pituch1, Julius W Kim1, Mahsa Talebian1, Jawad Fares1, Maciej S Lesniak2.   

Abstract

Amino acid deprivation is a strategy that malignancies utilize to blunt anti-tumor T-cell immune responses. It has been proposed that amino acid insufficiency in T-cells is detected by GCN2 kinase, which through phosphorylation of EIF2α, shuts down global protein synthesis leading to T-cell arrest. The role of this amino acid stress sensor in the context of malignant brain tumors has not yet been studied, and may elucidate important insights into the mechanisms of T-cell survival in this harsh environment. Using animal models of glioblastoma and animals with deficiency in GCN2, we explored the importance of this pathway in T-cell function within brain tumors. Our results show that GCN2 deficiency limited CD8+ T-cell activation and expression of cytotoxic markers in two separate murine models of glioblastoma in vivo. Importantly, adoptive transfer of antigen-specific T-cells from GCN2 KO mice did not control tumor burden as well as wild-type CD8+ T-cells. Our in vitro and in vivo data demonstrated that reduction in amino acid availability caused GCN2 deficient CD8+ T-cells to become rapidly necrotic. Mechanistically, reduced CD8+ T-cell activation and necrosis was due to a disruption in TCR signaling, as we observed reductions in PKCθ and phoshpo-PKCθ on CD8+ T-cells from GCN2 KO mice in the absence of tryptophan. Validating these observations, treatment of wild-type CD8+ T-cells with a downstream inhibitor of GCN2 activation also triggered necrosis of CD8+ T-cells in the absence of tryptophan. In conclusion, our data demonstrate the vital importance of intact GCN2 signaling on CD8+ T-cell function and survival in glioblastoma.

Entities:  

Keywords:  CD8+ T-cell; GCN2; Glioma; ISRIB

Mesh:

Substances:

Year:  2019        PMID: 31844909      PMCID: PMC6952559          DOI: 10.1007/s00262-019-02441-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  59 in total

1.  Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response.

Authors:  Akito Nakamura; Tadahiro Nambu; Shunsuke Ebara; Yuka Hasegawa; Kosei Toyoshima; Yasuko Tsuchiya; Daisuke Tomita; Jun Fujimoto; Osamu Kurasawa; Chisato Takahara; Ayumi Ando; Ryuichi Nishigaki; Yoshinori Satomi; Akito Hata; Takahito Hara
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-30       Impact factor: 11.205

2.  Regulated translation initiation controls stress-induced gene expression in mammalian cells.

Authors:  H P Harding; I Novoa; Y Zhang; H Zeng; R Wek; M Schapira; D Ron
Journal:  Mol Cell       Date:  2000-11       Impact factor: 17.970

3.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Authors:  Karolina Woroniecka; Pakawat Chongsathidkiet; Kristen Rhodin; Hanna Kemeny; Cosette Dechant; S Harrison Farber; Aladine A Elsamadicy; Xiuyu Cui; Shohei Koyama; Christina Jackson; Landon J Hansen; Tanner M Johanns; Luis Sanchez-Perez; Vidyalakshmi Chandramohan; Yen-Rei Andrea Yu; Darell D Bigner; Amber Giles; Patrick Healy; Glenn Dranoff; Kent J Weinhold; Gavin P Dunn; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-02-07       Impact factor: 12.531

Review 4.  Coping with stress: eIF2 kinases and translational control.

Authors:  R C Wek; H-Y Jiang; T G Anthony
Journal:  Biochem Soc Trans       Date:  2006-02       Impact factor: 5.407

5.  Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain.

Authors:  J Dong; H Qiu; M Garcia-Barrio; J Anderson; A G Hinnebusch
Journal:  Mol Cell       Date:  2000-08       Impact factor: 17.970

6.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

Authors:  David H Munn; Madhav D Sharma; Babak Baban; Heather P Harding; Yuhong Zhang; David Ron; Andrew L Mellor
Journal:  Immunity       Date:  2005-05       Impact factor: 31.745

Review 7.  Arginine and cancer.

Authors:  D Scott Lind
Journal:  J Nutr       Date:  2004-10       Impact factor: 4.798

8.  IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.

Authors:  Stefan Löb; Alfred Königsrainer; Derek Zieker; Björn L D M Brücher; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness
Journal:  Cancer Immunol Immunother       Date:  2008-04-17       Impact factor: 6.968

Review 9.  Nutrient and Metabolic Sensing in T Cell Responses.

Authors:  Jun Wei; Jana Raynor; Thanh-Long M Nguyen; Hongbo Chi
Journal:  Front Immunol       Date:  2017-03-09       Impact factor: 7.561

10.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.

Authors:  Roger Geiger; Jan C Rieckmann; Tobias Wolf; Camilla Basso; Yuehan Feng; Tobias Fuhrer; Maria Kogadeeva; Paola Picotti; Felix Meissner; Matthias Mann; Nicola Zamboni; Federica Sallusto; Antonio Lanzavecchia
Journal:  Cell       Date:  2016-10-13       Impact factor: 41.582

View more
  9 in total

1.  Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.

Authors:  Changlin Li; Hui Sun; Wei Wei; Qiuzi Liu; Yinglei Wang; Ying Zhang; Fuming Lian; Fangchao Liu; Chenchen Li; Kaicheng Ying; Hang Huo; Zhi Qi; Benyi Li
Journal:  Cell Oncol (Dordr)       Date:  2020-07-24       Impact factor: 6.730

Review 2.  Tryptophan metabolism in brain tumors - IDO and beyond.

Authors:  Michael Platten; Mirco Friedrich; Derek A Wainwright; Verena Panitz; Christiane A Opitz
Journal:  Curr Opin Immunol       Date:  2021-04-01       Impact factor: 7.486

3.  Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma.

Authors:  Jason Miska; Aida Rashidi; Catalina Lee-Chang; Peng Gao; Aurora Lopez-Rosas; Peng Zhang; Rachel Burga; Brandyn Castro; Ting Xiao; Yu Han; David Hou; Samay Sampat; Alex Cordero; Joshua S Stoolman; Craig M Horbinski; Mark Burns; Yana K Reshetnyak; Navdeep S Chandel; Maciej S Lesniak
Journal:  Sci Adv       Date:  2021-02-17       Impact factor: 14.136

4.  Roles of interacting stress-related genes in lifespan regulation: insights for translating experimental findings to humans.

Authors:  Anatoliy I Yashin; Deqing Wu; Konstantin Arbeev; Arseniy P Yashkin; Igor Akushevich; Olivia Bagley; Matt Duan; Svetlana Ukraintseva
Journal:  J Transl Genet Genom       Date:  2021-10-19

Review 5.  Breaking Bad: Autophagy Tweaks the Interplay Between Glioma and the Tumor Immune Microenvironment.

Authors:  Yuxiang Fan; Yubo Wang; Jian Zhang; Xuechao Dong; Pu Gao; Kai Liu; Chengyuan Ma; Gang Zhao
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

Review 6.  Immunomodulatory Effects of Tryptophan Metabolism in the Glioma Tumor Microenvironment.

Authors:  Yang Xu; Huikai Zhang; Qian Sun; Rongxin Geng; Fanen Yuan; Baohui Liu; Qianxue Chen
Journal:  Front Immunol       Date:  2021-10-01       Impact factor: 7.561

Review 7.  Protein synthesis, degradation, and energy metabolism in T cell immunity.

Authors:  Julia M Marchingo; Doreen A Cantrell
Journal:  Cell Mol Immunol       Date:  2022-01-04       Impact factor: 22.096

8.  Interplay between stress-related genes may influence Alzheimer's disease development: The results of genetic interaction analyses of human data.

Authors:  Anatoliy I Yashin; Deqing Wu; Konstantin Arbeev; Olivia Bagley; Igor Akushevich; Matt Duan; Arseniy Yashkin; Svetlana Ukraintseva
Journal:  Mech Ageing Dev       Date:  2021-03-30       Impact factor: 5.498

Review 9.  Stress relief for cancer immunotherapy: implications for the ER stress response in tumor immunity.

Authors:  Alex M Andrews; Megan D Tennant; Jessica E Thaxton
Journal:  Cancer Immunol Immunother       Date:  2020-10-26       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.